EP2097077A1

EP2097077A1 - Benzoyl peroxyde comprising compositions, at least one naphtoic acid derivative and at least one compound of polyurethane polymer-type or derivatives thereof, and their use

Info

Publication number: EP2097077A1
Application number: EP07858750A
Authority: EP
Inventors: Claire Mallard; Emmanuelle At
Original assignee: Galderma Research and Development SNC
Current assignee: Galderma Research and Development SNC
Priority date: 2006-11-28
Filing date: 2007-11-28
Publication date: 2009-09-09
Also published as: JP2013241469A; AU2007327358B2; BRPI0717699A2; AU2007327358A1; US8568704B2; CA2670599A1; RU2009124488A; MX2009005308A; RU2459612C2; FR2909000A1; CN101605537A; WO2008065306A1; JP2010520853A; US20100143285A1; KR20090085077A; FR2909000B1

Abstract

A composition for topical application comprising, in a physiologically acceptable environment, benzoyl peroxide, at least one naphthoic acid derivative and at least one compound of polyurethane polymer-type or derivatives thereof. The invention is characterized in that the said benzoyl peroxide and the said naphthoic acid derivative are in dispersed form in the said composition. The invention is particularly useful in human pharmacy or cosmetics.

Description

COMPOSITIONS COMPRISING BENZOYL PEROXIDE, AT LEAST ONE

NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE POLYURETHANE POLYMER COMPOUND OR DERIVATIVES THEREOF AND THEIR

USES

The present invention relates to compositions for topical application, and their uses as cosmetic or pharmaceutical products, said compositions being intended, in particular, for the treatment of acne.

Acne is a common multifactorial pathology that reaches skin rich in sebaceous glands (face, scapular region, arms and intertriginous regions). It is the most common dermatitis. The following five pathogenic factors play a determining role in the constitution of acne: 1. genetic predisposition; 2. overproduction of sebum (seborrhea);

3. androgens;

4. disorders of follicular keratinization (comedogenesis); and

5. bacterial colonization and inflammatory factors.

There are several forms of acne, all having in common the involvement of pilosebaceous follicles. These include acne conglobata, keloid acne, drug acne, recurrent acne, acne necrotic, acne neonatorum, premenstrual acne, acne rosacea, senile acne, solar acne, and acne vulgaris.

Acne vulgaris, also called polymorphous juvenile acne, is the most common. It includes four stages, but the passage through all stages is not mandatory:

Stage 1 corresponds to comedonal acne characterized by a large number of open and / or closed comedones and microcysts.

Stage 2, or papulopustular acne, is of mild to moderate severity. It is characterized by the presence of open and / or closed comedones, microcysts, but also red papules and pustules. It mainly affects the face and leaves few scars. Stage 3, or papulocomedonian acne, is more serious and extends to the back, thorax and shoulders. It is accompanied by a larger number of scars. Stage 4, or nodulocystic acne, is accompanied by numerous scars. It presents nodules as well as voluminous pustules violaceous and painful.

The different forms of acne described above can be treated with active agents such as anti-seborrhoeic agents and anti-infectious agents, for example benzoyl peroxide (in particular the product Eclaran® marketed by the company Pierre Fabre), with retinoids such as tretinoin (in particular the Retacnyl® product marketed by Galderma) or isotretinoin (Roaccutane® product marketed by Roche Laboratories), or by naphthoic acid derivatives. The naphthoic acid derivatives, such as, in particular, 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid, commonly known as adapalene (Differine® product marketed by Galderma), are widely described. and recognized as active ingredients as effective as tretinoin for the treatment of acne. The combination of several local treatments (antibiotics, retinoids, peroxides, zinc) is also used in dermatology to increase the effectiveness of the active ingredients and reduce their toxicity (Cunliffe WJ., J. Dermatol Treat., 2000, 1 1 (suppl2), S13-S14). The multiple application of different dermatological products can be quite heavy and exacting for the patient.

It is therefore understandable to seek to obtain a new effective treatment on dermatological conditions in a stable composition providing good cosmetics, allowing a single application and a pleasant use for the patient. Among this array of therapies proposed to the skilled person, nothing encouraged him to associate, in the same composition, benzoyl peroxide and a retinoid.

However, the formulation of such a composition poses several problems.

First, the effectiveness of benzoyl peroxide is related to its decomposition when it is brought into contact with the skin. Indeed, it is the oxidizing properties of the free radicals produced during this decomposition that lead to the desired effect. Also, in order to maintain benzoyl peroxide optimal efficiency, it is important to prevent its decomposition before use, ie during storage.

But benzoyl peroxide is an unstable chemical compound that makes it difficult to formulate in finished products. The solubility and stability of benzoyl peroxide have been studied by Chellquist et al. in ethanol, propylene glycol and various mixtures of polyethylene glycol 400 (PEG 400) and water (Chellquist EM and Gorman WG, Pharm Res., 1992, Vol 9: 1341-1346). Benzoyl peroxide is particularly soluble in PEG400 and ethanol as shown in the following table:

This document also specifies that the stability of the benzoyl peroxide is strongly influenced by the chemical composition of the formulation and by the storage temperature. Benzoyl peroxide is extremely reactive and degrades in solution at low temperatures due to the instability of its peroxide bond.

The authors thus note that the benzoyl peroxide in solution degrades more or less rapidly in all the solvents studied according to the type of solvent and its concentration. The degradation times of benzoyl peroxide in PEG 400 (0.5 mg / g), in ethanol and in propylene glycol are respectively 1, 4, 29 and 53 days at 40 ° C. Such degradation does not allow the preparation of a product for sale.

Thus, to limit the problem of rapid instability of benzoyl peroxide in solution, it has proven advantageous to formulate benzoyl peroxide in dispersed form.

However, this type of formulation is not entirely satisfactory insofar as there is always a deterioration of benzoyl peroxide in the finished product.

Another difficulty to overcome for the preparation of a composition comprising both benzoyl peroxide and a retinoid is that most retinoids are particularly sensitive to natural oxidation, visible light and ultraviolet, and - AT -

Since benzoyl peroxide is a strong oxidant, the chemical compatibility of these compounds in the same formulation poses numerous problems of stability from a physical and chemical point of view.

A stability study of two retinoids was performed by combining two commercial products, one containing retinoid (tretinoin or adapalene) and the second containing benzoyl peroxide (B. Martin et al., Br.J.Dermatol. (1998) 139, (suppl.52), 8-11). The presence of the benzoyl peroxide formulation causes a very rapid degradation of the oxidation-sensitive retinoids: it is measured that 50% of the tretinine degrades in 2 hours, and 95% in 24 hours. In the composition in which the retinoid is adapalene, no degradation of adapalene has been measured for 24 hours. This study confirms that benzoyl peroxide degrades and degrades oxidation-sensitive retinoids over time by progressively releasing benzoic acid into finished products. However it is clear that the degradation of benzoyl peroxide and retinoids is undesirable insofar as it affects the effectiveness of the composition containing them.

There was no incentive to combine these two active agents to obtain a stable emulsion-type composition knowing that it was usually known that the presence of benzoyl peroxide destabilized chemically and physically this type of composition.

In addition, attempts have been made to develop compositions making it possible to increase the topical penetration of certain active agents by including, in compositions, polyurethane polymer type compounds or their derivatives (patent EP 0299 758). Avita®, marketed by BERTEK Pharmaceuticals Inc., is an example. It contains in particular 0.025% by weight relative to the total weight of the solubilized tretinoin composition in gel or cream-type compositions and containing polyurethane polymers (type 2 polyolprepolymers marketed by Bertek Pharmaceuticals Inc.) in order to limit desquamation, irritation and drying of the skin.

It is found that the Applicant has surprisingly demonstrated that polyurethane polymers can promote the topical penetration of insoluble compounds, dispersed or suspended in pharmaceutical compositions, such as in particular benzoyl peroxide and acid derivatives. naphthoic. In view of the foregoing, a problem to be solved by the invention is to provide compositions which are stable and less irritating than those of the prior art, comprising a combination of benzoyl peroxide with at least one acid derivative. naphthoic, the assets being in dispersed form, and at least one polyurethane polymer type compound or derivatives thereof, said composition to promote the topical penetration of the active ingredients in dispersed form.

Thus, the invention firstly relates to a composition, preferably a pharmaceutical composition, in particular for topical application, comprising in a physiologically acceptable medium at least: (i) benzoyl peroxide, (ii) a derivative of naphthoic acid, and (iii) a polyurethane polymer compound or derivatives thereof, said naphthoic acid derivative and said benzoyl peroxide being in dispersed form in said composition.

By active in dispersed form according to the invention is meant an active ingredient in the form of solid particles, suspended in a given vehicle. Such particles in particular have a size greater than 10 microns.

Advantageously, the particle size of the retinoid and of benzoyl peroxide is such that at least 80% by number of the particles, and preferably at least 90% by number of the particles, have a diameter of less than 25 μm and at least 99% in number of particles have a diameter less than 100 microns.

By physiologically acceptable medium is meant a medium compatible with the skin, mucous membranes and / or integuments.

The second subject of the present invention is the use of a composition as described above for the preparation of a pharmaceutical composition intended for the treatment and / or prevention of dermatological disorders linked to a disorder of keratinization relating to the differentiation and cell proliferation, and in particular to treat pathologies selected from acne vulgaris, comedoniennes, papulopustuleuse, papulocomédoniennes, nodulocystiques, acnes conglobata, keloid acne necrosis, recurrent miliatic acne, necrotic acne, neonatorum acne, occupational acne, polymorphic acne rosacea, senile acne, solar acne and drug acne

The composition according to the invention comprises benzoyl peroxide, at least one derivative of naphthoic acid, and at least one polyurethane polymer type compound or derivatives thereof.

Naphthoic acid is a compound of the formula:

By derivative of naphthoic acid is meant the compounds of formula (I):

where R represents a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having 1 to 10 carbon atoms or a substituted or unsubstituted cycloaliphatic radical.

By linear or branched alkyl radical having from 1 to 4 carbon atoms, is preferably meant methyl, ethyl, propyl or butyl radicals.

Alkoxy radical having 1 to 10 carbon atoms is preferably methoxy, ethoxy, propoxy, butoxy, hexyloxy or decyloxy. The term "cycloaliphatic radical" preferably means mono or polycyclic radicals such as the 1-methylcyclohexyl radical or the 1-adamantyl radical.

Among the naphthoic acid derivatives which can be used in the compositions according to the invention, 6- [3- (1-adamantyl) -

4-methoxyphenyl] -2-naphthoic acid (adapalene), 6- [3- (1-adamantyl) -4-hydroxyphenyl] -2-naphthoic acid, 6- [3- (1-adamantyl) -4- -Decyloxyphenyl] -2-naphthoic acid and 6- [3- (1-adamantyl) -4-hexyloxyphenyl] -2-naphthoic acid.

The abovementioned naphthoic acid derivatives are generally in a form dispersed in the composition according to the invention. The insoluble naphthoic acid derivatives are thus distributed homogeneously in the composition according to the invention.

In the compositions according to the invention, the naphthoic acid derivatives are used at concentrations of less than or equal to 10% by weight relative to the total weight of the composition, and preferably are between 0.001% and 10% by weight. relative to the total weight of the composition, and preferably between 0.01% and 5%, more preferably between 0.03% and 2%, and most preferably from 0.1% to 0.3% by weight relative to total weight of the composition.

Throughout this text, unless otherwise specified, it is understood that when concentration ranges are given, they include the upper and lower limits of said range.

Advantageously, the naphthoic acid derivative used in the compositions according to the invention is 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid (adapalene). The concentration of the adapalene used in the composition according to the invention is then between 0.01% and 0.5%, more preferably between 0.05% to 0.03% and between 0.1% and 0.3%, in particular at a concentration of 0.1% and at a concentration of 0.3%.

In the compositions according to the invention, benzoyl peroxide is used at concentrations ranging from 1 to 10% by weight, more particularly from 2 to 7% by weight, even more preferably from 2.5 to 5% by weight relative to to the total weight of the composition. Benzoyl peroxide may also be used in the free form or in an encapsulated form in adsorbed form or absorbed in any porous carrier.

It may be, for example, benzoyl peroxide encapsulated in a polymeric system consisting of porous microspheres, for example micro-sponges sold under the name Microsponges P009A Benzoyl peroxide by the company Cardinal Healthcare.

The composition according to the invention further comprises polyurethane polymer type compounds or derivatives thereof. Polyurethane polymers are polyalkylene glycols as described in patent EP 0 299 758 and marketed by Bertek Pharmaceuticals Inc. The polyurethane polymers according to the invention have unique properties which confer advantageous properties for them. applications in the cosmetic and pharmaceutical fields. Indeed, polyurethane polymers significantly influence the deposition of certain agents on and in the skin, and this by their high molecular weight. In addition, the polyurethane polymers preferentially remain in the upper layers of the skin.

Among the polyurethane polymers that can be used in the compositions according to the invention, mention may be made of the polyurethane polymers of general formula:

in which:

R is CH3 or H; n is an integer selected so that the polyurethane polymer has a molecular weight of at least 1000, preferably n is between 5 and 55; and m is a number from 1 to 6 inclusive.

By way of non-limiting example of polyurethane polymers that may be used in the compositions according to the invention, taken alone or as a mixture, mention may be made of Polyolprepolymer-2 (PP-2) and polyolprepolymer-14 (PP-14) (named poly [oxy (1,2-methyl-ethanediyl)], α-hydroxy-hydroxy-polymer with 1,1 ' methylene-bis-, isocyanatocyclohexane]), and polyolprepolymer-15 (PP-15) (named poly (oxy-1,2-ethanediyl)], α-hydroxy-hydroxy-polymer with 1,1 ' -methylene-bis- [4, isocyanatocyclohexane]) alone or in admixture. These three polymers are marketed by Bertek Pharmaceuticals Inc., and meet the above general formula with m varying from 1 to 4 and for which, respectively, n = 12 for PP-2, n = 51 for PP-2. 14 and n = 8 for the PP-15.

Among the polyurethane polymers that can be used in the compositions according to the invention, polyolprepolymer-2 (PP-2) is advantageously chosen.

In the compositions according to the invention, the compounds of the polyurethane polymer type or derivatives thereof are used at concentrations of less than or equal to 20%, preferably of between 0.5% and 20% by weight relative to total weight of the composition and more preferably between 1% and 10%, preferably at a concentration of less than 7% and in particular 1%, 3% or 5%. Such low concentrations of polyurethane polymers advantageously make it possible to reduce the toxicity and general irritation of the composition according to the invention.

The polyurethane polymers in the composition according to the invention have anti-irritant and moisturizing properties that may be particularly advantageous in the case of adapalene and benzoyl peroxide formulations. Indeed, naphthoic acid derivatives and benzoyl peroxide can be irritating and have a drying action on the skin. It is therefore interesting to reduce the induced irritation in order to increase the doses.

The compositions of the present invention may be in any of the galenical forms normally used for topical application, especially in the form of aqueous, hydroalcoholic or oily dispersions, lotion-type dispersions, aqueous, anhydrous or lipophilic gels, liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft, semi-liquid or solid consistency cream type, gel-cream or ointment or still microemulsions, micro capsules, micro particles or vesicular dispersions of ionic and / or nonionic type.

Preferably, the compositions according to the invention are in the form of lotions, gel-creams, gels or creams.

Those skilled in the art will take care to choose the excipients constituting the compositions according to the invention as a function of the desired dosage form and so that the advantageous properties of the composition according to the invention are respected.

The composition according to the invention may further comprise one or more of the following ingredients: a) one or more gelling agents or suspending agents, b) one or more chelating agents, c) one or more wetting agents, d) one or more preservatives e) one or more emulsifiers f) one or more wetting surfactants g) one or more lipophilic excipients making up the fatty phase h) an aqueous phase i) one or more additives

In one of the preferred aspects of the invention, the composition is in the form of a gel. In a preferred embodiment, the gelling agents used for carrying out the invention are pH-independent agents.

By independent pH gelling agent is meant a gelling agent capable of conferring a sufficient viscosity on the composition to maintain the retinoid and the benzoyl peroxide in suspension, even under the influence of a pH variation due to the release of benzoic acid by the benzoyl peroxide.

By way of nonlimiting example of gelling agents or suspending agents that can be used in the compositions according to the invention, mention may be made of Acrylates / C10-30 Alkyl Acrylate

Crosspolymer sold under the name Pemulen TR-1 or Pemulen TR-2 by the company Noveon, Avicel CL-611 sold by the company FMC Biopolymer, the so-called non-electrolyte sensitive carbomers sold under the name, Ultrez 20 ®, 1382 or Carbopol ETD2020NF® by the company Noveon, polysaccharides with, by way of nonlimiting examples, xanthan gum such as Xantural180® sold by Kelco, guar gum, chitosans, cellulose and its derivatives such as hydroxypropylmethylcellulose in especially the product sold under the name Methocel E4M premium by Dow Chemical or hydroxyethylcellulose, in particular, the product sold under the name of Natrosol HHX 250® by the company Aqualon, the family of magnesium aluminum silicates such as Veegum K sold by the company Vanderbilt, the family of acrylic polymers coupled to hydrophobic chains such as PEG-150 / decyl / SMDI copolymer sold under the name of Aculyn 44 (polycondensate comprising at least as elements, a polyethylene glycol with 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis (4-cyclohexylisocyanate) (SMDI), at 35% by weight in a mixture of propylene glycol (39%) and water (26%)), the family of modified starches such as modified potato starch sold under the name Solanace Structure or mixtures thereof. and the gelling agents of the polyacrylamide family, such as the Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 mixture sold under the name Simulgel 600 PHA by the company Seppic, the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture, for example that sold under the name Sepigel 305 by the company Seppic, the carrageenan family in particular divided into four major families: K, λ, β, ω such as Viscarin® and Gelcarin® sold by the company IMCD

The gelling agent as described above may be used at preferential concentrations ranging from 0.1 to 15% and, more preferably, from 0.5 to 5%.

As a preferred gelling agent, mention may be made of carbomers, polyacrylamides, acrylic polymers coupled to hydrophobic chains, cellulose and its derivatives such as hydroxypropylmethylcellulose or hydroxyethylcellulose, polysaccharides and especially xanthan gum, and in particular especially those sold under the names Simulgel 600, PEG-150 / decyl / SMDI copolymer, Methocel E4M premium, Natrosol HHX 250®, XanturaM 80® Carbopol Ultrez 20.

Among the chelating agents, there may be mentioned as non-limiting examples ethylene diamine tetraacetic acid (EDTA), diethylene triamine pentaacetic acid

(DTPA), ethylene diamine-di (O-hydroxyphenyl acetic acid) (EDDHA), hydroxy-2-ethylene diamine triacetic acid (HEDTA), ethyldiamine-di (O-hydroxy-p- methyl phenyl) acetic acid (EDDHMA) and ethylene diamine di (5-carboxy-2-hydroxyphenyl) acetic acid (EDDCHA).

As a preferred chelating agent, mention may be made of ethylene diamine tetraacetic acid (EDTA) sold in particular under the name Titriplex III®.

Among the wetting agents whose role is to reduce the surface tension and to allow greater spreading of the liquid, it is preferable to use, without this list being limiting, compounds such as propylene glycol, dipropylene glycol and propylene glycol dipelargonate. , lauroglycol and ethoxydiglycol, block copolymers of ethylene oxide and propylene oxide such as those sold under the name Synperonic PE / L44, Synperonic PE / L62, alone or in admixture.

As a preferred wetting agent, mention may be made of propylene glycol.

Among the preserving agents, mention may be made, by way of non-limiting examples, of benzoic acid and its derivatives with benzyl alcohol, benzalkonium chloride, sodium benzoate, bronopol, chlorhexidine, chlorocresol and its derivatives, ethyl alcohol, phenethyl alcohol, phenoxyethanol, potassium sorbate, diazolidinyl urea, parabens such as propyl paraben or methyl paraben, alone or in mixtures.

As a preferred preservative, mention may be made of parabens and phenoxyethanol or benzalkonium chloride alone or as a mixture.

The composition according to the invention may comprise one or more emulsifiers. The surfactant emulsifiers are amphiphilic compounds which have a hydrophobic part having an affinity for the oil and a hydrophilic part having an affinity for water thus creating a link between the two phases. Ionic or nonionic emulsifiers thus stabilize the oil / water emulsions by adsorbing at the interface and forming lamellar layers of liquid crystals.

The emulsifying power of nonionic surfactants is closely related to the polarity of the molecule. This polarity is defined by the HLB (Hydrophile / Lipophilic Balance). High HLB indicates that the hydrophilic moiety is predominant, and conversely, low HLB indicates that the lipophilic moiety is predominant. For example, HLB values greater than about 10 correspond to hydrophilic surfactants.

Surfactants can be classified, according to their structure, under the generic terms "ionic" (anionic, cationic, amphoteric) or "nonionic". Nonionic surfactants are surfactants that do not dissociate into ions in water and are therefore insensitive to pH changes.

Nonionic surfactants are particularly well suited for the preparation of oil-in-water type emulsions, object of the present invention. Thus, the emulsifying system, component of the emulsion of the invention, comprises at least one nonionic surfactant, hydrophilic predominant fraction, that is to say having a high HLB, greater than about 10.

Examples of nonionic surfactants with high HLB include sorbitan esters such as POE (20) sorbitan monooleate sold as "Tween 80" (HLB = 15); POE (20) sorbitan monostearate sold under the name "Tween 60" (HLB = I 4.9); fatty alcohol ethers such as POE (21) stearyl ether (HLB = 15.5), or ceteareth 20 sold under the name "Eumulgin B2" by Cognis (HLB 15.5).

Preferably, said high HLB nonionic surfactants have an HLB between 10 and 18.

Examples of low-HLB nonionic surfactants are:

(lipophilic) sorbitan esters, such as sorbitan monostearate (sold as Span 60 by Uniqema), glycerol esters (sold under the name Cutina

GMSVPH by Cognis) such as glycerol monostearate (Cutina GMS from Cognis), low HLB sucrose esters such as sucrose distearate.

Preferably, said nonionic surfactants exhibiting low HLB have an HLB of less than 10.

The nonionic surfactants may be used alone or in a mixture of two or more of them to form the emulsifying system comprising the emulsion of the invention. Preferably, one or more pairs of "high HLB nonionic surfactant" / "low HLB nonionic surfactant" will be used as the emulsifying system. It may in particular be a nonionic emulsifying system comprising at least a nonionic surfactant having an HLB greater than about 10 and at least one nonionic surfactant having an HLB of less than about 10.

The ratio of each of the two surfactants forming the aforementioned pair is most often determined by the calculation of the required HLB of the fat phase used.

As preferred emulsifiers, mention may be made of hydrophilic emulsifiers of the Tween 80, Giyceryi Monostearate & POE Stearate type sold under the name Arlacel 165FL® by Uniqema; PEG 6 stearate and PEG 32 stearate sold under the name TEFOSE 1500 by GATTEFOSSE, lipophilic emulsifiers of the Glucate SS (methyl glucose sesquistearate) type and Glucamate SSE 20 (PEG 20 methyl glucose sesquistearate) sold by Amerchol, Polyoxyethylene (21) Stearyi Ether sold under the name Brij721 ® by the company Uniqema

The composition according to the invention may also comprise a fatty phase. This fatty phase may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.

As an example of mineral oil, there may be mentioned, for example, paraffin oils of different viscosities such as Primol 352®, Marcol 82®, Marcol 152® sold by the company Esso.

As vegetable oil, there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.

As animal oil, mention may be made of lanolin, squalene, fish oil, mink oil with the derivative squalane sold under the name Cosbiol® by Laserson.

As synthetic oil, mention may be made of an ester such as cetearyl isononanoate such as the product sold under the name Cetiol SNPH® by Cognis France, diisopropyl adipate, and the product sold under the name Ceraphyl 230® by the company. ISF, isopropyl palmitate, such as the product sold under the name Crodamol IPP® by Croda, caprylic capric triglyceride such as Miglyol 812® sold by HuIs / Lambert Rivière.

As volatile or non-volatile silicone oil, mention may be made of a dimethicone such as the product sold under the name Q7-9120 Silicone Fluid with a viscosity of 20 to 12500 is or the product sold under the name ST-Cyclomethicone 5NF® by Dow. Corning.

It will also be possible to use solid fatty substances such as natural or synthetic waxes. In this case, those skilled in the art will adapt the heating temperature of the preparation depending on the presence or absence of these solids.

For the composition according to the invention, mineral oils and silicone oils and more particularly Marcol 152® and ST-Cyclomethicone 5 NF are preferred.

The composition according to the invention may also comprise emollient agents. Examples of emollient agents are glycerine, sorbitol, sugars (for example glucose, lactose), PEGs (for example Lutrol E400), urea, acids and the like. amines (for example serine, citrulline, alanine).

The compositions of the invention may furthermore comprise any additive usually used in the cosmetic or pharmaceutical field such as surfactants, neutralizers (for example, triethanolamine, 10% sodium hydroxide solution, citric acid / sodium buffer). citrate, succinic acid / sodium succinate buffer), sunscreens, antioxidants, fillers, electrolytes, dyes, usual or inorganic or organic bases or acids, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and skin-protecting agents such as allantoin, propenetrating agents, or a mixture of these optionally, a stabilizer benzoyl peroxide (for example sodium docusate, C14-16 sodium olefin sulfonate). Of course, those skilled in the art will take care to choose this or these optional additional compounds, and / or their quantity, in such a way that the properties advantageous of the composition according to the invention are not, or not substantially impaired.

These additives may be present in the composition in a proportion of 0.001% to 20% by weight relative to the total weight of the composition.

In a particular embodiment of the invention, the composition is in the form of an oil-in-water emulsion (O / W) of the lotion, cream or gel-cream type and comprises:

from 0.1% to 0.3% of a naphthoic acid derivative; from 1% to 10% of benzoyl peroxide;

from 1% to 10% of one or more polyurethane polymers or derivatives;

from 0.1% to 7%; in a particular embodiment of 0.1% to 3% of one or more gelling agents or suspending agents;

from 0% and preferably from 0.01 to 1.5% of one or more chelating agents; from 0.1% to 10% of one or more wetting agents;

from 0.1% to 20% of an emollient agent;

from 0.1% to 30% fat phase;

from 0% to 3%; in a particular mode of 0.01% to 3% of preservatives; from 0% to 10% of emulsifiers;

0 to 2% of stabilizing agents.

In another particular embodiment of the invention, the composition is in gel form and comprises: from 0.1% to 0.3% of a naphthoic acid derivative;

from 1% to 10% of benzoyl peroxide;

from 1% to 10% of one or more polyurethane polymers or derivatives;

from 0.1% to 7%; in a particular embodiment of 0.1% to 3% of one or more gelling agents or suspending agents; from 0% and preferably from 0.01 to 1.5% of one or more chelating agents;

from 1% to 10% of one or more wetting agents;

from 0.1% to 20% of an emollient agent;

from 0% to 3% in a particular mode of 0.01% to 3% of preserving agents;

from 0% to 2% of stabilizing agents; In another particular embodiment of the invention, the composition is in cream gel form and comprises:

from 0.1% to 0.3% of a naphthoic acid derivative;

from 1% to 10% of benzoyl peroxide; from 1% to 10% of one or more polyurethane polymers or derivatives;

from 0% to 1.5% of one or more chelating agents;

from 1% to 10% of one or more wetting agents; from 0.1% to 20% of an emollient agent;

from 0.1 to 30% fat phase;

from 0.01% to 3% of preserving agents;

from 0% to 2% of stabilizing agents;

In a particular embodiment of the invention, the composition is in lotion form and comprises:

from 0.1% to 0.3% of a naphthoic acid derivative;

from 0% to 1.5% of one or more chelating agents;

from 0.1% to 30% fat phase;

from 0.01% to 3% of preserving agents;

from 0% to 10% of emulsifiers;

from 0% to 2% of stabilizing agents.

In a particular embodiment of the invention, the composition is in cream form and comprises:

from 1% to 10% of one or more polyurethane polymers or derivatives; from 0.1% to 7%; in a particular embodiment of 0.1% to 3% of one or more gelling agents or suspending agents;

from 0.01% to 1.5% of one or more chelating agents;

from 0.1% to 30% fat phase;

from 0.01% to 3% of preserving agents.

from 0% to 10% of emulsifiers;

from 0% to 2% of stabilizing agents;

The invention also relates to a method for preparing a composition as described above. Such a process is characterized in that it comprises the step of mixing a physiologically acceptable vehicle comprising at least one derivative of naphthoic acid with benzoyl peroxide and with at least one polyurethane polymer type compound or derivatives thereof, said naphthoic acid derivative and benzoyl peroxide being in dispersed form in said composition.

The introduction of other excipients and optional additives will be based on the chemical nature of the compounds and the chosen dosage form.

The preparation of a composition according to the invention is carried out in 3 or 5 stages according to the chosen galenic form, the 2 additional steps being carried out solely for the preparation of the emulsion type forms such as creams, lotions, gel-creams.

The introduction of the polyolprepolymer in either step is dependent on the lipophilic or hydrophilic nature of the polyolprepolymer. Thus, the type PP-2 polyolprepolymer of lipophilic nature is introduced into the fatty phase for the emulsions and after the neutralization step for the gels. The PP-15 type hydrophilic polyolprépolymer is introduced into the active aqueous phase.

The preparation of a composition according to the invention is thus carried out according to the following main process: a) mixing the naphthoic acid derivative with at least one wetting agent, in water, until said naphthoic acid derivative is perfectly dispersed, in order to obtain the active phase 1;

b) mixing the benzoyl peroxide with at least one wetting agent, in water, until said benzoyl peroxide is perfectly dispersed, in order to obtain the active phase 2;

c) is solubilized in water, if necessary hot, one or more gelling agents (with the exception of polyacrylamide), optionally a chelating agent, one or more preservatives, one or more emollients, one or more emulsifiers, a suspending agent, a stabilizing agent. Stirring and optional heating is maintained to homogeneity to obtain the aqueous phase.

d) Optionally to obtain an emulsion, at least lipophilic emulsifiers, oils and / or solid fatty substances are mixed with preservatives in order to obtain the fatty phase;

e) The two active phases obtained respectively in a) and b) are mixed. A unique active phase is obtained.

f) Optionally, said fatty phase obtained in d) is introduced into the aqueous phase obtained in c) to obtain an emulsion;

g) The single active phase obtained in e) is added to the phase obtained in f) for the emulsions or in the phase obtained in c) for the cream gels and gels.

h) Optionally, the polyacrylamide is introduced with stirring into the phase obtained in g). Maintain agitation until perfect homogeneity.

i) Optionally, for the cream gels, the oil is introduced with stirring to the mixture obtained in step g) or h).

j) If necessary, a gelling agent neutralizing agent is introduced. In the case of an emulsion, it will be introduced into the phase obtained in step g). In the case of a gel, it will be introduced into the phase obtained in step g) or h). In the case of a cream gel, it will be introduced in the phase obtained in i). The polyurethane polymer-type compound or derivatives thereof being introduced into the aqueous active phase obtained in a) or b) or in the fatty phase obtained in step d) or after step j) as a function of its lipophilic or hydrophilic nature.

The preparation of a composition according to the invention is thus carried out according to the following alternative method:

The active ingredients are mixed in the 1 ^st step of the process described above; thus steps a) and b) are replaced by step a '): a') The naphthoic acid derivative, the benzoyl peroxide with at least one wetting agent, is mixed in water up to said benzoyl peroxide and said naphthoic acid derivative are fully dispersed to provide a single active phase.

The process is then continued as described from step c).

More specifically, the main process for preparing the composition according to the invention comprises the following steps:

Step a: preparation of the active phase 1:

In a beaker, purified water is introduced with stirring, the active ingredient (adapalene), the wetting agents (Synperonic type PE / L62, Synperonic PE / L44, propylene glycol). It is stirred until perfect dispersion.

Step b: Preparation of the active phase 2

In a beaker, purified water is introduced with stirring, the active principle (benzoyl peroxide), wetting agents (Synperonic PE / L62 type, Synperonic PE / L44, propylene glycol). It is stirred until perfect dispersion.

Step c: Preparation of the aqueous phase

In a beaker, purified water is introduced with stirring, if necessary while hot, and the gelling agent (s) (with the exception of Simulgel 600PHA), optionally the chelating agent (EDTA type), the emollients (glycerin type). ), the preservative (methyl paraben type), the emulsifiers, the suspending agent (Avicel type), the stabilizing agent (sodium docusate type). Step d: (optional): Preparation of the fat phase:

In an auxiliary beaker, the emulsifiers (Glucate SS, Glucamate SSE 20, Brij 721, Teflon, Arlacel 165FL, Tween 80) are introduced with stirring, the oily compounds (isostearic olepal type, Cetiol SN, Crodamol DA, Speziol C18, Miglyol 812, Cosbiol, Marcol 152, ST-Cyclomethicone 5NF) and preservatives (phenoxyethanol and propyl paraben type). The mixture is heated until homogenization and the volatile silicone is introduced if the latter is present in the composition.

Step e: the mixing of the active phases:

At a temperature below 40 ° C, the two active phases obtained respectively in a) and b) are mixed, stirring is maintained until perfect homogenization;

Stage f (optional): Emulsification: At the temperature of 60.degree. C. and with stirring, the fatty phase is introduced slowly into the aqueous phase in order to carry out the emulsification. The heating is maintained for 5 minutes, then allow the product to cool slowly. The stirring is adjusted according to the viscosity.

Steps d) and f) are optional and are performed solely for the preparation of emulsion type forms such as creams, lotions.

Step g: Introduction of the single active phase obtained in e) in the aqueous phase obtained in c) for the cream gels and gels or in the phase obtained in f) for the emulsions.

Step h (optional): Addition of Simulgel 600PHA

Simulgel 600PHA is introduced with stirring into the phase obtained in g). Maintain agitation until perfect homogeneity.

Step i (optional): Addition of oil for cream gels

With stirring, the oil is added to the mixture obtained in step g) or h).

Step i: Neutralization: At a temperature below 40 ° C., if necessary, the neutralizing agent of the gelling agent (triethanolamine type, 10% sodium hydroxide solution, acid buffer citric / sodium citrate, succinic acid / sodium succinate buffer) is added if necessary, up to pH 5.5 +/- 0.5. The product then takes on a thicker consistency. At the end of the manufacturing, the pH is checked again. If necessary, the water adjustment is performed. The product is homogenized one last time in order to ensure the good dispersion of the active ingredient Adapalene (microscopic observation revealing a homogeneous dispersion and without aggregates), then the product is conditioned.

The polyurethane polymer type compound is preferably a polyolprepolymer which is introduced during steps a) or b) (for gels or gel cream or emulsion formulations comprising a hydrophilic polymer) or in step d) (for emulsion formulations comprising a lipophilic polymer) or after step j) (for gel formulations comprising a lipophilic polymer) depending on its lipophilic or hydrophilic nature.

More specifically, the alternative method for preparing the composition according to the invention comprises the following steps:

Step a Preparation of the single active phase: In a beaker, purified water is introduced with stirring, the active principles (Adapalene and benzoyl peroxide), the wetting agents (Synperonic PE / L62 type, Synperonic PE / L44, propylene glycol). It is stirred until perfect dispersion.

Step b Preparation of the aqueous phase

In a beaker, purified water is introduced with stirring, if necessary while hot, and the gelling agent (s) (with the exception of Simulgel 600PHA), optionally the chelating agent (EDTA type), the emollients (glycerin type). ), the emulsifiers, the preservative (methyl paraben type), the suspending agent (Avicel type), the stabilizing agent (sodium docusate type).

Step c (optional): Preparation of the fatty phase:

In an auxiliary beaker, the emulsifiers (Glucate) are introduced with stirring.

SS, Glucamate SSE 20, Brij 721, Teflon, Arlacel 165FL, Tween 80), the oily compounds (isostearic olepal type, Cetiol SN, Crodamol DA, Speziol C18, Miglyol 812,

Cosbiol, Marcol 152, ST-Cyclomethicone 5NF) and preservatives (type phenoxyethanol and propyl paraben). The mixture is heated until homogenization and the volatile silicone is introduced if the latter is present in the composition.

Step d (optional): Emulsification: At the temperature of 60 ° C and with stirring, the fatty phase is introduced slowly into the aqueous phase in order to carry out the emulsification. The heating is maintained between 3 and 8 minutes, then the product is allowed to cool. The stirring is adjusted according to the viscosity.

Steps c) and d) are optional and are performed solely for the preparation of emulsion type forms such as creams, lotions.

Step e: Introduction of the single active phase obtained in a) in the aqueous phase obtained in b) (for gels and cream gels) or in the phase obtained in d) (for emulsions).

Step f (optional): Addition of Simulgel 600PHA

Simulgel 600PHA is introduced with stirring into the phase obtained in e). Maintain agitation until perfect homogeneity.

Step g (optional): Addition of the oil for cream gels

With stirring the oil is added to the mixture obtained in step e) or f).

Step h: Neutralization: At a temperature below 40 ° C, the neutralizing agent of the gelling agent (triethanolamine type, 10% sodium hydroxide solution, citric acid / sodium citrate buffer, succinic acid / sodium succinate buffer) is if necessary, up to pH 5.5 +/- 0.5. The product then takes on a thicker consistency. At the end of the manufacturing, the pH is checked again. If necessary, the water adjustment is performed. The product is homogenized one last time in order to ensure the good dispersion of the active ingredient Adapalene (microscopic observation revealing a homogeneous dispersion and without aggregates), then the product is conditioned.

The polyurethane polymer type compound is preferably a polyolprepolymer which is introduced during step a) (for gels or cream gels or emulsions comprising a hydrophilic polymer) or during the step c) (for emulsion formulations comprising a lipophilic polymer) or after step h) (for gel formulations comprising a lipophilic polymer) depending on its lipophilic or hydrophilic nature.

The present invention also relates to the composition as described above as a medicament.

The invention also relates to the use of the novel composition as described above in cosmetics and dermatology.

In particular, the invention relates to the use of a composition as described above for the preparation of a pharmaceutical composition intended for the treatment and / or prevention of dermatological disorders linked to a disorder of keratinization relating to the differentiation and cell proliferation, and in particular to treat vulgar, comedonal, papulopustular, papulocomedonous, nodulocystic acne, conglobata acne, keloid neck acne, recurrent miliatic acne, necrotic acne, neonatorum acne, occupational acne rosacea, senile acnes, solar acnes and medicated acnes.

More particularly, the invention relates to the use of a composition as described above for the preparation of a pharmaceutical composition for preventing or treating acne vulgaris.

Preferably, said compositions according to the invention are administered topically.

In addition, the invention also relates to the cosmetic use of a composition according to the invention for the treatment of acne-prone skin, to combat the oily appearance of the skin or the hair, in the protection against the harmful to the sun or in the treatment of physiologically oily skin.

The present invention will now be illustrated by means of the examples and the physical and chemical stability data presented below: By study of the physical stability of the formulations, the realization of a macroscopic and microscopic observation at ambient temperature, 40 ° C carried out at T1 month, T2mois and optionally at T + 1 δjours.

Microscopic observation makes it possible to evaluate the quality of the dispersion of the two active ingredients. Adapalene is observed in fluorescent light while benzoyl peroxide is observed in polarized light.

The characterization of the finished product is completed by a measurement of the flow threshold and viscosity. For the measurement of the flow threshold, a HAAKE rheometer of type VT550 with a measurement mobile SVDIN is used.

The rheograms are carried out at 25 ° C, at the shear rate of 4 s ^"1 '20s ^{" 1} and

100s ^"1 (γ) and by measuring the shear stress By flow threshold (τθ expressed in Pascal) we mean the force required (minimum shear stress) to overcome the Van der Waals cohesive forces and to provoke the shear stress. 'flow.

The flow threshold is equivalent to the value found at the shear rate of

4s-1.

For viscosity measurement, Brookfield RVDVII + or LVDVII + viscometers are used. The range of measurable viscosities with the two types of Brookfield are as follows:

- RVDVI l +: 10OcP - 40McP

- LVDVII +: 15cP - 6McP

It will be considered that at the initial time TO: - a cream or a cream gel if the viscosity is greater than 3000OcP at the initial time TO. a lotion if the viscosity is less than 3000OcP at the initial time TO (Lucinda Bushe, ACPS October 22, 2003 Pharmaceutical Nomenclature-Issues and Challenges)

Chemical stability is ensured by an HPLC assay of the actives.

The result is expressed in mg / g of adapalene and benzoyl peroxide and in% relative to the expected title. EXAMPLE 1 Gel Formulation Containing 2.5% Benzoyl Peroxide, 0.1% Adapalene and 2-Polyol Prepolymer

The formula is prepared according to the procedure described above:

Constituents Content (% m / m)

Benzoyl peroxide 2.50% Adapalene 0.10% Propylene glycol 4.00% Synperonic PE / L44 0.20% EDTA 0.10% Glycerin 4.00%

Polyolpepolymer-2 1.00% Sodium Docusate 0.05% Simulgel 600PHA 4.00% Purified Water qs 100%

> Physical stability:

Ti month Tδweek T2mois

Macroscopic appearance TA Identical to TO Identical to TO Identical to TO

40 ° C Same as TO Same as TO Same as TO

Microscopic appearance TA Identical to TO Identical to TO Identical to TO

40 ° C Same as TO Same as TO Same as TO

PH TA 3.71 3.78 3.82

40 ° C 3.56 3.51 3.54

Rheology Rheology 127/17 97/13 127/18 4s-1 / 20s-1 / 100s-1 8/275 7/233 2/279

> Chemical stability:

^> Adap awl

Benzoyl peroxide

Example 2 Gel Formulation Containing Benzoyl Peroxide 2.5% of Adapalene at 0.1% and Polvolprepolvmer-15

The formula is prepared according to the procedure described above:

Constituents Content (% m / m)

Benzoyl peroxide 2.50

Adapalene 0.10

Propvlene qlvcol 4.00

Svnperonic PE / L44 0.20

EDTA 0.10

Glycerin 4.00

Polvolprépolvmère-15 1.00

Sodium Docusate 0.05

Simulαel 600PHA 4.00

Purified water αsp 100%

Stabi lity Data:> Physical Stabi lity:

> Chemical stability: ^> Adap awl

Benzoyl peroxide Example 3 Gel Formulation Containing Adapalene at 0.1% and Benzoyl Peroxide at 2.5% and Polyprepolymer at 15%

Constituents Content (% m / m)

Benzoyl peroxide 2.50

Adapalene 0.10

Propvlene qlvcol 4.00

Svnoeronic PE / L44 0.20

EDTA 0.10

Glycerin 4.00

Polyolpolymer-15 5.00

Sodium Docusate 0.05

Simulqel 600PHA 4.00

Purified water αsp 100%

Stabi lity Data:> Physical Stabi lity:

> Chemical stability:

^> Adapalene

Benzoyl peroxide Example 4 Cream Formulation Containing 0.1% Adapalene and 2.5% Benzovel Peroxid and Polvol Prepolymer-2

The formula is prepared according to the procedure described above:

Constituents Content (% m / m)

Benzoyl peroxide 2.50

Adapalene 0.10

Propylene glycol 4.00

Synperonic PE / L44 0.20

Sodium Docusate 0.05

Propylene glycol 2.00

EDTA 0.10

Carbopol Ultrez 20 0.40

Glycerin 3.00

Glucamate SSE 20 3.50

Glucate SS 3.50

Perhydrosqualene 6.00

ST-Cyclomethicone 5 NF 13,00

Polyolpepolymer-2 1.00

Purified water qs 100

Triethanolamine qs pH 5.5 ± 0.5

STABILITY DATA:

CHEMICAL STABILITY:

^ adapalene

Example 5 Cream Formulation Containing 0.3% Adapalene and 5% Benzoyl Peroxide and Polvol Prepolymer-2 The Formula is Prepared According to the Procedure Described Above

Constituents Content (% m / m) Benzoyl Peroxide 5.00 Adapalene 0.30

Dipropylene glycol 5.00

Synperonic PE / L44 0.20

Glycerin 7.00

Xantural 180 0.4

Eumulgin B2 PH 3.00

Arlacel 165FL 3.00

Speziol C18 Pharma 2.00

Miglyol 812 N 7.00

ST-Cyclomethicone 5 NF 6.00

Simulgel 600 PHA 2.50 polyol-prepolymer-2 3.00

Purified water qs 100

Sodium hydroxide qs pH 5.5 ± 0.5

STABILITY DATA:

PHYSICAL STABILITY

CHEMICAL STABILITY:

^ adapalene

^ BENZOYL PEROXIDE Example 6: Lotion Formulation Containing 0.3% Adapalene and 1% Benzoyl Peroxide and Polvol Prepolymer-2

The formula is prepared according to the procedure described above:

Ten u r (% m / m)

Benzoyl peroxide 1, 00

Adapalene 0.30

Dipropylene Glycol 3.00

Synperonic PE / L44 0.20

Methyl paraben 0.15

Avicel CL-61 1 1 .50

Brij 721 3.00

Arlacel 165FL 3.00

Propyl paraben 0.05

Perhydrosqualene 5.00

Cetiol SN PH 5.00

Simulgel 600 PHA 1 .50

Polyolpolymer-2 1.00

Purified water qs 100%

Triethanolamine qsppH 5.5 ± 0,

Stability data:

> Physical stability:

Characterizations at TO

Macroscopic appearance White lotion

Good dispersion of the 2 assets.

adapalene

90% <20 μm

Microscopic appearance 99% <50 μm

BENZOYL

PEROXIDE

95% <25 μm

99% <100 μm

PH 5.868

Haake data (4s-1 / 20s- 24/41/87 viscosity 1 / 100S-1)

Brookfield LVDVII + 21211cP

(S63; 5rpm) T15 days Ti month

Macroscopic appearance TA Identical to TO Identical to TO

4O ⁰ C Same as TO Same as TO

Microscopic appearance TA Identical to TO Identical to TO

4O ⁰ C Same as TO Same as TO

PH TA 5.42 5.13

4O ⁰ C 4.34 3.96

Haake Rheology 21/36/74 18/33/70 4s-1 / 20s-1 / 100s-1

Brookfield Viscosity 16916cP 15453cP LVDVII + (S63; 5rpm)

> Chemical stability: ^> Adapalene

Example 7 Cream Gel Formulation Containing 0.1% Adapalene and 2.5% Benzoyl Peroxide and Polyol Prepolymer-15

The formula is prepared according to the procedure described above:

Constituents Content (% m / m)

Benzoyl peroxide 2.50

Adapalene 0.10

Propylene glycol 5.00

Synperonic PE / L44 0.20

EDTA 0.10

Glycerin 5.00

Xantural 180 0.10

Carbopol Ultrez 20 0.70

Marcol 152 7.00 polyol-prepolymer-15 1.00

Purified water qs 100

Sodium hydroxide 10% m / m qsp pH 5.5 ± 0.5

Stability data:

> Physical stability:

Characterizations at TO

Macroscopic appearance White cream gel

Good dispersion of the 2 assets.

adapalene

Microscopic appearance 90% <20 μm

99% <50 μm

BENZOYL PEROXIDE

95% <25 μm

99% <100 μm

PH 5.169

Haake data (4s-1 / 20s-54/89/150 viscosity 1 / 100S-1)

Brookfield RVDVII + 31634 cP

(S27; 5rpm) Chemical stability: ^> Adapalene

Benzoyl peroxide EXAMPLE 8 Thick Cream Gel Formulation Containing 0.10% Adapalene and 2.5% Benzoyl Peroxide and Polyol Prepolymer-2

The formula is prepared according to the procedure described below:

Constituents Content (% m / m)

Benzoyl peroxide 2.50 Adapalene 0.10 Propylene glycol 6.00 Synperonic PE / L44 0.20 Glycerine 5.00

ST-Cyclomethicone 5NF 7.00 Simulgel 600 PHA 4.00 Polyolpepolymer-2 1.00 Purified water qs 100

Stability Data:> Physical Stability:

Chemical stability: ^> Adap awl

Time- ^ TO Ti month

Conditions of stabilityΨ

IΔg / g 0.10 0.10

% title 100 100 10 expected

40 ° C g / g NA 0.10

% title NA 100 expected 15

Benzoyl peroxide

Claims

claims

A composition comprising, in a physiologically acceptable medium, at least:

(i) benzoyl peroxide, (ii) a derivative of naphthoic acid, and

(iii) a polyurethane polymer compound or derivatives thereof, said naphthoic acid derivative and said benzoyl peroxide being in dispersed form in said composition.

2. Composition according to claim 1, characterized in that the derivative of naphthoic acid is a compound of formula (I):

where R represents a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having 1 to 4 carbon atoms, an alkoxy radical having 1 to 10 carbon atoms or a cycloaliphatic radical.

3. Composition according to claim 1 or 2, characterized in that the concentration of the naphthoic acid derivative is between 0.001% and 10%, more preferably between 0.01% and 5% by weight of the total weight of the composition. .

4. Composition according to one of the preceding claims, characterized in that the naphthoic acid derivative is chosen from 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid, the acid 6- [3- (1-adamantyl) -4-hydroxyphenyl] -2- naphthoic acid, 6- [3- (1-adamantyl) -4-decyloxyphenyl] -2-naphthoic acid and 6- [3- (1-adamantyl) -4-hexyloxyphenyl] -2-naphthoic acid.

5. Composition according to one of claims 1 to 4, characterized in that the naphthoic acid derivative is 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid.

6. Composition according to claim 5, characterized in that the concentration of 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid is between about 0.01% and 0.5% by weight relative to to the total weight of the composition.

7. Composition according to Claim 6, characterized in that the concentration of 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid is approximately 0.1% by weight relative to the total weight. of the composition.

8. Composition according to claim 6, characterized in that the concentration of 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid is about 0.3% by weight relative to the total weight of the composition.

9. Composition according to any one of the preceding claims, characterized in that the concentration of benzoyl peroxide is between 1 and 10% by weight relative to the total weight of the composition, preferably between 2 and 7%.

10. Composition according to Claim 9, characterized in that the concentration of benzoyl peroxide is between 2.5% and 5% by weight relative to the total weight of the composition.

Composition according to any one of the preceding claims, characterized in that the polyurethane polymer-type compound is chosen from polyolprepolymer type 2, polyolprepolymer type 14 and polyolprepolymer type 15, taken alone or as a mixture .

12. Composition according to claim 10, characterized in that the polyurethane polymer type compound is the polyolprepolymer type 2.

13. Composition according to any one of the preceding claims, characterized in that the concentration of the polyurethane polymer type compound is between 0.5% and 20% by weight relative to the total weight of the composition, and preferably between 1%. and 10%.

14. Composition according to claim 10, characterized in that the concentration of the polyurethane polymer type compound is 1%, 3%, or 5% by weight of the total weight of the composition.

15. Composition according to any one of the preceding claims, characterized in that it is in the form of aqueous, aqueous-alcoholic or oily dispersions, lotion-type dispersions, aqueous, anhydrous or lipophilic gels, type emulsions. emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft consistency, semi-liquid liquid or solid type cream, gel-cream or ointment or microemulsions, micro capsules, micro particles or vesicular dispersions of ionic and / or nonionic type.

16. Composition according to claim 15, characterized in that it is in the form of a gel.

17. Composition according to claim 15, characterized in that it is in the form of a cream.

18. Composition according to claim 15, characterized in that it is in the form of a lotion.

19. Composition according to claim 15, characterized in that it is in the form of a gel-cream.

20. Composition according to one of the preceding claims, characterized in that it may further comprise one or more of the following ingredients: a) one or more gelling agents or suspending agents, b) one or more chelating agents, c) one or more wetting agents, d) one or more preservatives. e) one or more emulsifiers f) one or more wetting surfactants g) one or more lipophilic excipients making up the fatty phase h) an aqueous phase i) one or more additives

21. Composition according to claim 20, characterized in that it comprises in water: from 0.1% to 0.3% of a naphthoic acid derivative;

from 1 to 10% of benzoyl peroxide;

from 1% to 10% of one or more polyurethane polymers or derivatives;

from 0.1% to 7% of one or more gelling agents or suspending agents;

from 0% to 1.5% of one or more chelating agents; from 1% to 10% of one or more wetting agents;

from 0.1% to 20% of an emollient agent; and

from 0.01% to 3% of preserving agents

from 0 to 2% of stabilizing agent.

22. Composition according to claim 20, characterized in that it comprises in water:

from 0.1% to 0.3% of a naphthoic acid derivative;

from 1% to 10% of benzoyl peroxide;

from 1% to 10% of one or more polyurethane polymers or derivatives; from 0.1% to 7% of one or more gelling agents or suspending agents;

from 0% to 1.5% of one or more chelating agents;

from 1% to 10% of one or more wetting agents;

from 0.1% to 20% of an emollient agent;

from 0.1% to 30% fat phase; from 0% to 3% of preserving agents;

- from 0 to 10% of emulsifiers

from 0 to 2% of stabilizing agent.

23. A composition according to any one of the preceding claims as a medicament.

24. Use of a composition according to one of claims 1 to 23 for the preparation of a pharmaceutical composition for the treatment and / or prevention of dermatological disorders related to a disorder of keratinization on differentiation and on the cell proliferation.

25. Use according to claim 24, characterized in that the dermatological disorders related to a disorder of keratinization relating to differentiation and cell proliferation are selected from vulgar, comedonal, papulopustular, papulocomedonous, nodulocystic acne, conglobata acnes, keloid acne, recurrent miliatic acne, necrotic acne, neonatorum acne, occupational acne, polymorphic acne, rosacea, senile acne, solar acne and medicinal acne.

26. Use according to claim 25, characterized in that the dermatological disorders related to a disorder of keratinization on differentiation and cell proliferation are common acne.

27. Cosmetic use of a composition according to any one of claims 1 to 23 for the treatment of acne-prone skin, to combat the oily appearance of the skin or hair, in the protection against the harmful aspects of the sun or in the treatment of physiologically oily skin.

28. A process for preparing a composition according to claims 1 to 23 comprising the following steps: a) mixing the naphthoic acid derivative with at least one wetting agent, at least one chelating agent, at least one gelling agent, optionally hydrophilic emulsifiers and emollients, in water, until said naphthoic acid derivative is perfectly dispersed, in order to obtain the active phase 1; b) The benzoyl peroxide is mixed with at least one wetting agent, at least one chelating agent, at least one gelling agent, optionally hydrophilic emulsifiers and emollients, in water, until said benzoyl peroxide is perfectly dispersed, in order to obtain the active phase 2; c) One or more gelling agents (with the exception of polyacrylamide), optionally a chelating agent, one or more preservatives, one or more gelling agents (with the exception of polyacrylamide), are solubilized in water, if necessary while hot; ), one or more emollients, one or more emulsifiers, a suspending agent, an agent stabilizing. Stirring and optional heating is maintained to homogeneity to obtain the aqueous phase. d) optionally to obtain an emulsion, at least lipophilic emulsifiers, oils and / or solid fatty substances are mixed with preservatives in order to obtain the fatty phase; e) The two active phases obtained respectively in a) and b) are mixed. A unique active phase is obtained. f) optionally, said fatty phase obtained in d) is introduced into the aqueous active phase obtained in c) to obtain an emulsion; g) The single active phase obtained in e) is added to the phase obtained in f) for the emulsions or in the phase obtained in c) for gels and cream gels, h) Optionally, the polyacrylamide is introduced with stirring in the phase obtained in g); agitation is maintained until perfect homogeneity. i) Optionally, for the cream gels, the oil is introduced with stirring to the mixture obtained in step g) or h). j) If necessary, a gelling agent neutralizing agent is introduced.

29. Process for preparing a composition according to claims 1 to 23 comprising the following steps:

The active ingredients are mixed in the 1 ^st step of the method according to claim 28; steps a) and b) are replaced by step a ') as described below: a') the naphthoic acid derivative, the benzoyl peroxide with at least one wetting agent, is mixed in with water, until said benzoyl peroxide and said naphthoic acid derivative are fully dispersed to obtain a single active phase; the process is then continued as described from step c) according to claim 28.